eHealth (EHTH)
(Delayed Data from NSDQ)
$4.86 USD
-0.17 (-3.38%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.86 USD
-0.17 (-3.38%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
Arthur J. Gallagher Announces Cairnstone Financial Buyout
by Zacks Equity Research
Arthur J. Gallagher's (AJG) buyout of Cairnstone Financial will boost the acquirer's product offerings.
Why Should You Hold Marsh & McLennan in Your Portfolio?
by Zacks Equity Research
Riding high on a steady top line, sturdy financial position and inorganic growth, Marsh & McLennan (MMC) has high potential to reap benefits for investors.
3 Reasons Why eHealth (EHTH) Is a Great Growth Stock
by Zacks Equity Research
eHealth (EHTH) possesses solid growth attributes, which could help it handily outperform the market.
Marsh & McLennan Unit Launches Cloud-Based Tech Solution
by Zacks Equity Research
Marsh & McLennan (MMC) arm Mercer introduces Mercer Mobility Management Platform in partnership with ServiceNow.
3 Reasons Growth Investors Will Love eHealth (EHTH)
by Zacks Equity Research
eHealth (EHTH) could produce exceptional returns because of its solid growth attributes.
Analysts Estimate eHealth (EHTH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
EHealth (EHTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
eHealth (EHTH) Up 259% in a Year: What's Driving the Stock?
by Zacks Equity Research
Shares of eHealth (EHTH) is expected to continue the bull run backed by solid fundamentals and initiatives to ramp up growth.
EHealth (EHTH) Misses Q4 Earnings Estimates
by Zacks Equity Research
eHealth (EHTH) delivered earnings and revenue surprises of -18.27% and 0.19%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
EHealth (EHTH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
EHealth (EHTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Momentum Investors Will Love eHealth (EHTH)
by Zacks Equity Research
Does eHealth (EHTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Marsh & McLennan (MMC) in Focus: Stock Moves 5.3% Higher
by Zacks Equity Research
Marsh & McLennan (MMC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
eHealth (EHTH) Catches Eye: Stock Jumps 6.4%
by Zacks Equity Research
eHealth (EHTH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
eHealth (EHTH) Reports Preliminary Results for Q4 and FY18
by Zacks Equity Research
eHealth expects Q4 net income between $24.3 million and $27.3 million on revenues of $133.5 million to $135.5 million.
CME Group Gains 26% in a Year: Will the Rally Continue?
by Zacks Equity Research
Shares of CME Group (CME) rally 26.1% in a year, backed by solid fundamentals and initiatives to ramp up growth.
Diversified Business, Buyouts to Aid Allstate's Growth in 2019
by Zacks Equity Research
Allstate's (ALL) diversified portfolio along with recent acquisitions position it for growth in 2019.
Why You Should Keep Marsh & McLennan (MMC) in Your Portfolio
by Zacks Equity Research
Banking on top-line improvement, inorganic growth and strong liquidity, Marsh & McLennan (MMC) holds great potential to garner heavy returns for investors.
eHealth's Medicare Application Businesses Offer a Big Boost
by Zacks Equity Research
Robust commission revenues, medicare application business and a probable expansion of enrollment volume help eHealth (EHTH) emerge as a prospective bet for yield-seeking investors.
Marsh & McLennan's (MMC) Unit Launches China Desk in Dubai
by Zacks Equity Research
Marsh & McLennan's (MMC) subsidiary introduces China desk in Dubai to benefit from the growing commercial links amid China, the Middle East and Africa.
The Zacks Analyst Blog Highlights: Cincinnati Financial, National General, State Auto, Arthur J. and eHealth
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cincinnati Financial, National General, State Auto, Arthur J. and eHealth
5 Insurance Stocks Set to Keep Winning Streak Alive in 2019
by Zacks Equity Research
We zeroed on five solid picks set to keep the growth momentum alive in 2019 banking on operational efficiency and favorable macro backdrop.
Here's Why You Should Buy Willis Towers Watson Stocks Now
by Zacks Equity Research
Willis Towers Watson's (WLTW) organic growth, momentum in the exchange business and strong capital position make the stock apt to buy.
Arthur J. Gallagher Gains 18% YTD: Will the Rally Continue?
by Zacks Equity Research
Shares of Arthur J. Gallagher & Co. (AJG) rallied 18% year to date, backed by solid fundamentals and initiatives to ramp up growth.
Marsh & McLennan's Arm Acquires Otis-Magie Insurance Agency
by Zacks Equity Research
Marsh & McLennan's (MMC) subsidiary purchases Otis-Magie Insurance Agency to enrich customer experience in northern Minnesota.
Arthur J. Gallagher Expands Globally With Boston Marks Buyout
by Zacks Equity Research
Arthur J. Gallagher's (AJG) buyout of Boston Marks with operations in New Zealand, Australia and United Kingdom is in tandem with growing international footprint.
New Strong Buy Stocks for December 7th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday